HJLI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Oct 2021 @ 12:00):

Stats
今日成交量	221 867
平均成交量	777 480
市值	98.32M
EPS	$-0.280 ( 2021-08-11 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.491 (4.73%)

Insider Trading

Date	Person	Action	Amount	type
2021-05-18	Berman Robert Andrew	Buy	3 000	Common Stock, $0.00001 par value
2020-07-18	Duhay Francis	Buy	62 500	Common Stock
2020-07-18	Duhay Francis	Buy	100 000	Stock Option
2019-06-07	Biodyne Holding, S.a.	Sell	684 813	Common Stock

INSIDER POWER
0.00
Last 4 transactions
Buy: 165 500 \| Sell: 684 813

音量相关性

長: 0.03 (neutral)

短: 0.15 (neutral)

Signal:(69.18) Neutral

Hancock Jaffe 相关性

10 最正相关
SPRT	0.906
XOG	0.893
PAIC	0.886
TLGT	0.884
CYN	0.881
ICAD	0.874
LSAK	0.873
RAPT	0.868
SVAC	0.866
AMD	0.864

10 最负相关
ARDS	-0.91
IBRX	-0.895
VINC	-0.888
NETE	-0.883
HRMY	-0.878
ALRS	-0.87
TCBIO	-0.865
RPTX	-0.859
BOTZ	-0.856
VIEW	-0.853

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Hancock Jaffe 相关性 - 货币/商品

0.29
( neutral )

0.71
( moderate )

-0.10
( neutral )

0.12
( neutral )

0.47
( neutral )

-0.75
( moderate negative )

Hancock Jaffe 财务报表

Annual	2023
营收:	$0
毛利润:	$-546 000 (0.00 %)
EPS:	$-1.910

FY	2023
营收:	$0
毛利润:	$-546 000 (0.00 %)
EPS:	$-1.910

FY	2022
营收:	$0
毛利润:	$-525 000 (0.00 %)
EPS:	$-2.16

FY	2020
营收:	$4 252.00
毛利润:	$4 252.25 (100.00 %)
EPS:	$-0.0106

Financial Reports:

No articles found.

Hancock Jaffe

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 9 full-time employees. The firm is developing biologic-based solutions that are designed to be life enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease (ESRD). The firm is in the process of developing bioprosthetic implantable devices for cardiovascular disease. The Company’s Bioprosthetic Heart Valve (BHV), is a bioprosthetic, pig heart valve designed to function like a native heart valve, and designed to provide a patient greater functional performance than available devices. The Company’s product Venous Valve is a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency (CVI), which occurs because of damage to the valves of the veins in the legs after patients develop blood clots in the deep venous system.